Dexamethasone-sparing Approach Including NEPA Against Emesis Caused by Cisplatin
Status:
Active, not recruiting
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
This study evaluates the possibility to reduce the total dose of dexamethasone, when
administered with NEPA, to prevent chemotherapy-induced nausea and vomiting (CINV) in
Non-Small Cell Lung Cancer (NSCLC) patients receiving a cisplatin-based chemotherapy